Ads
related to: Kite Pharma, Inc
Search results
Kite Pharma's CAR T-Cell Therapy Wins European Approval In Refractory Leukemia Setting
Benzinga via Yahoo Finance· 2 years agoThe European Commission has approved Gilead Science Inc (NASDAQ: GILD) company Kite Pharma's CAR...
Europe Approves First CAR T-Cell Therapy For B-Cell Lymphoma In 30 Years to Improve Upon Standard of...
Benzinga via Yahoo Finance· 2 years agoThe European Commission approved Kite Pharma's, a Gilead Sciences Inc (NASDAQ: GILD) Yescarta...
U.S. Supreme Court rejects Bristol Myers cancer-drug patent fight with Gilead
Reuters via Yahoo Finance· 2 years agoWASHINGTON (Reuters) -The U.S. Supreme Court on Monday rebuffed a bid by Bristol Myers Squibb Co's...
US Supreme Court Throws Out Bristol Myers Appeal On Cancer-Drug Related Patent With Gilead
Benzinga via Yahoo Finance· 2 years agoThe U.S. Supreme Court turned away an appeal made by rebuffed efforts made by Bristol Myers Squibb...
Arcellx Inc (ACLX) Reports Q3 2023 Financial Results and Business Updates
GuruFocus.com via Yahoo Finance· 6 months agoArcellx Inc (NASDAQ:ACLX) announces promising updates on CART-ddBCMA trial with median follow-up of 22 months. Financials show $482.7 million in cash reserves, funding operations into 2026.
Arcellx Inc (ACLX) Q1 2024 Earnings: Narrower Losses and Revenue Surge
GuruFocus.com via Yahoo Finance· 2 weeks agoRevenue: Reported at $39.26 million for Q1 2024, an increase from $17.91 million in Q1 2023, surpassing estimates of $20.67 million. Net Loss: Recorded at $7.2 million for Q1 2024, significantly ...
Arcellx (RCLX) Down on Hold for Lead Program CART-ddBCMA
Zacks via Yahoo Finance· 11 months agoArcellx's (ACLX) study on lead program CART-ddBCMA for treating adult patients with relapsed or...
FDA Demands "Boxed Warning" to CAR T-Cell Therapy Labels
Zacks via Yahoo Finance· 4 months agoThe FDA directs companies like NVS, BMY, GILD and others to add "boxed warning" to the labels of...
